How does the FDA explain HRT timing effects

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, starting hormone therapy close to the time menopause begins is associated with more favorable cardiovascular effects, while starting many years after menopause may carry higher risks, especially related to the heart, blood vessels, and clotting. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

How the FDA describes this timing effect

According to the WHI, the way the body responds to estrogen may change as a woman ages. According to FDA.gov, if hormone therapy is begun when a woman is relatively young and recently menopausal, arteries are generally still flexible. In this setting, estrogen tends to behave more supportively. However, according to FDA Drug Safety Communication, if hormones are started 10 or more years after menopause, arteries may already have more plaque buildup. When that is the case, estrogen may stimulate vessel walls in ways that may raise the chance of a heart attack, stroke, or a blood clot.

According to FDA.gov, the window for use with a more favorable risk profile is around the time menopause symptoms begin, not long after they have passed. All clinical decisions about timing should be made with a qualified prescriber.

What the FDA emphasizes

• Start low, use the lowest effective dose, and re-evaluate regularly: According to FDA.gov, this approach helps keep risks as small as possible at any age.
• Hormone therapy is approved for symptom relief, not disease prevention: According to FDA.gov, the FDA does not recommend using hormone therapy to prevent heart disease, dementia, or aging-related issues.
• Health history matters: Conditions such as prior clots, stroke, certain cancers, or active heart disease may affect whether hormone therapy is appropriate — a qualified prescriber should evaluate individual circumstances.
• Transdermal routes (patch, gel) may carry lower clot risk: According to FDA-approved prescribing information, route of administration may influence certain safety outcomes.

Why timing changes risk

Before menopause and in the early menopausal years, vessel walls may respond to estrogen in a calming, widening way. Over time, without estrogen, cholesterol and inflammation may make vessels more rigid. According to the WHI, introducing estrogen into a vessel that already has plaque may be less predictable and may shift the risk profile. This is why beginning therapy many years later may present a different risk picture.

According to FDA.gov, when used for real symptoms, at the appropriate time, and in the appropriate patient, commercially available hormone therapy may be a reasonable option. A qualified prescriber is best positioned to evaluate whether timing and therapy are right for an individual patient.